CliffMapSee the sample

CliffMap Score

Find which big pharma must buy your asset

Built for small-biotech CEOs preparing to partner, out-license or sell: a ranked buyer list for your asset, in minutes.

  • Shortlist €149
  • Deal Path €490
  • Dossier €990
  • One-time, per asset
How it works3 steps

From your asset to a buyer list in three moves.

  1. AssetPick the therapeutic area of your asset
  2. RankingPharmas sorted by how soon they need to buy
  3. Buyer listEach tier adds depth: deal-path fit, then comparable deals

The score

One score per pharma, in five areas

An open, ranked number for each big pharma: the revenue it loses to patent expiry, how soon, and how little its own pipeline fills the gap.

5 areas

Sample

Your buyer list, ranked

A sample shortlist for a Phase 2 oncology asset, with made-up names and scores. No other index ranks big pharmas by how urgently they must buy and cites every number to a public filing.

Sample data
  • Pharma A#1 · Score 94
  • Pharma B#2 · Score 91
  • Pharma C#3 · Score 88
  • Pharma D#4 · Score 84
  • Pharma E#5 · Score 81
  • Pharma F#6 · Score 77
  • Pharma G#7 · Score 73
  • Pharma H#8 · Score 70
  • Pharma I#9 · Score 66
  • Pharma J#10 · Score 62

Sample only. Not a real ranking of any company.